Diamond Biotechnology Co., Ltd.

As of June 30, 2026, Diamond Biotechnology Co., Ltd. carries a market capitalization of 1.13B, placing it among publicly traded companies globally. Its enterprise value stands at 1.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Diamond Biotechnology Co., Ltd. has 39.49M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Diamond Biotechnology Co., Ltd. maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Diamond Biotechnology Co., Ltd.'s stock has declined approximately 68.10% over the past 52 weeks. The 50-day moving average sits at 23.39, while the 200-day moving average is 36.95.

As of June 30, 2026, Diamond Biotechnology Co., Ltd. holds 249.67M in cash and equivalents against 203.96M in total debt, resulting in a net debt position of 16.62M. Total book value stands at 575.20M, with working capital of 384.83M providing operational flexibility.

Diamond Biotechnology Co., Ltd.'s most recent stock split took place on August 27, 2025 with a 517:608 split ratio.